Company intelligence / Profile preview

Anthrax

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

Anthra Pharmaceuticals was a specialty biopharmaceutical company focused on developing and commercializing innovative therapies for cancer and urological diseases. The company is best known for developing Valstar (valrubicin), an anthracycline derivative approved by the FDA in 1998 for the intravesical treatment of BCG-refractory bladder cancer. Anthra's technology focused on modifying existing chemotherapeutic agents to improve their safety profile and enable localized delivery. The company was acquired by Medeva PLC in 1999 for approximately $50 million, and its lead product continues to be a standard of care for specific bladder cancer populations.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Sanofi-Synthelabo

Beyond the preview

Go deeper on Anthrax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anthrax.

Explore the full profile